De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Sartorius Stedim Biotech Toekomstige groei

Future criteriumcontroles 4/6

Sartorius Stedim Biotech zal naar verwachting groeien in winst en omzet met respectievelijk 30.3% en 10.1% per jaar. De winst per aandeel zal naar verwachting groeien met 29.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.3% zijn.

Belangrijke informatie

31.2%

Groei van de winst

31.7%

Groei van de winst per aandeel

Life Sciences winstgroei	26.2%
Inkomstengroei	10.5%
Toekomstig rendement op eigen vermogen	13.8%
Dekking van analisten	Good
Laatst bijgewerkt	18 Oct 2024

Recente toekomstige groei-updates

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 21

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Apr 21

Recent updates

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Not Quite Adding Up

Oct 15

Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?

Aug 11

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Jul 21

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Jul 12

Sartorius Stedim Biotech (EPA:DIM) Has A Somewhat Strained Balance Sheet

May 13

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Apr 21

With A 26% Price Drop For Sartorius Stedim Biotech S.A. (EPA:DIM) You'll Still Get What You Pay For

Apr 20

Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)

Feb 19

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear

Dec 22

Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?

Dec 01

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

Nov 10

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

Apr 23

Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly

Feb 07

Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?

Jan 20

Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet

Nov 09

Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today

Oct 20

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Oct 03

We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt

Jul 26

Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?

Jul 09

Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value

Jun 21

Sartorius Stedim Biotech (EPA:DIM) Could Easily Take On More Debt

Apr 21

Here's Why I Think Sartorius Stedim Biotech (EPA:DIM) Is An Interesting Stock

Apr 03

We Like Sartorius Stedim Biotech's (EPA:DIM) Earnings For More Than Just Statutory Profit

Feb 24

Winst- en omzetgroeiprognoses

ENXTPA:DIM - Toekomstschattingen van analisten en financiële gegevens uit het verleden (EUR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3,364	451	395	842	12
12/31/2025	3,009	344	316	754	12
12/31/2024	2,785	220	290	668	11
9/30/2024	2,736	161	504	866	N/A
6/30/2024	2,747	170	305	706	N/A
3/31/2024	2,716	255	169	636	N/A
12/31/2023	2,776	310	273	746	N/A
9/30/2023	2,959	460	113	625	N/A
6/30/2023	3,170	635	162	675	N/A
3/31/2023	3,356	717	137	606	N/A
12/31/2022	3,493	876	182	612	N/A
9/30/2022	3,381	681	125	552	N/A
6/30/2022	3,259	625	193	584	N/A
3/31/2022	3,094	559	322	661	N/A
12/31/2021	2,887	414	378	702	N/A
9/30/2021	2,639	523	355	623	N/A
6/30/2021	2,393	469	367	590	N/A
3/31/2021	2,143	398	310	506	N/A
12/31/2020	1,910	336	258	417	N/A
9/30/2020	1,743	299	299	414	N/A
6/30/2020	1,600	255	243	365	N/A
3/31/2020	1,520	254	216	345	N/A
12/31/2019	1,441	235	174	310	N/A
9/30/2019	1,393	247	142	291	N/A
6/30/2019	1,336	238	21	261	N/A
3/31/2019	1,274	223	88	270	N/A
12/31/2018	1,212	208	51	227	N/A
9/30/2018	1,172	185	57	226	N/A
6/30/2018	1,121	173	N/A	225	N/A
3/31/2018	1,093	162	N/A	196	N/A
12/31/2017	1,081	161	N/A	175	N/A
9/30/2017	1,073	151	N/A	165	N/A
6/30/2017	1,089	157	N/A	169	N/A
3/31/2017	1,075	157	N/A	146	N/A
12/31/2016	1,052	154	N/A	157	N/A
9/30/2016	1,009	145	N/A	146	N/A
6/30/2016	971	142	N/A	129	N/A
3/31/2016	926	136	N/A	155	N/A
12/31/2015	884	118	N/A	143	N/A
9/30/2015	850	111	N/A	150	N/A
6/30/2015	781	89	N/A	128	N/A
3/31/2015	734	76	N/A	113	N/A
12/31/2014	684	72	N/A	111	N/A
9/30/2014	646	71	N/A	93	N/A
6/30/2014	620	67	N/A	110	N/A
3/31/2014	604	68	N/A	97	N/A
12/31/2013	588	66	N/A	90	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei DIM ( 30.3% per jaar) ligt boven de spaarquote ( 1.2% ).

Winst versus markt: De winst van DIM ( 30.3% per jaar) zal naar verwachting sneller groeien dan de French markt ( 12.3% per jaar).

Hoge groeiwinsten: De winst van DIM zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van DIM ( 10.1% per jaar) zal naar verwachting sneller groeien dan de markt French ( 5.7% per jaar).

Hoge groei-inkomsten: De omzet van DIM ( 10.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen DIM zal naar verwachting over 3 jaar laag zijn ( 13.3 %).

Sartorius Stedim Biotech Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 8.8% to €216

Consensus EPS estimates fall by 17%

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

Consensus EPS estimates fall by 26%

Price target decreased by 7.8% to €229

Recent updates

New minor risk - Earnings quality

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Share Price Not Quite Adding Up

Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?

Price target decreased by 8.8% to €216

Consensus EPS estimates fall by 17%

Sartorius Stedim Biotech S.A. Just Missed Earnings - But Analysts Have Updated Their Models

Second quarter 2024 earnings: EPS misses analyst expectations

New major risk - Financial position

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Now 23% overvalued

Sartorius Stedim Biotech (EPA:DIM) Has A Somewhat Strained Balance Sheet

Sartorius Stedim Biotech S.A. Just Missed EPS By 26%: Here's What Analysts Think Will Happen Next

With A 26% Price Drop For Sartorius Stedim Biotech S.A. (EPA:DIM) You'll Still Get What You Pay For

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of €0.69 per share

Weak Statutory Earnings May Not Tell The Whole Story For Sartorius Stedim Biotech (EPA:DIM)

New minor risk - Profit margin trend

Dividend of €0.69 announced

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Sartorius Stedim Biotech S.A. has filed a Follow-on Equity Offering in the amount of €1.2 billion.

Consensus EPS estimates fall by 26%

Sartorius Stedim Biotech S.A. to Report Nine Months, 2024 Results on Oct 17, 2024

Sartorius Stedim Biotech S.A.'s (EPA:DIM) Popularity With Investors Is Clear

Investor sentiment improves as stock rises 16%

Is Sartorius Stedim Biotech (EPA:DIM) Using Too Much Debt?

Price target decreased by 7.8% to €229

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

Investor sentiment improves as stock rises 16%

Consensus EPS estimates fall by 25%

Price target decreased by 9.7% to €274

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 18%

Does Sartorius Stedim Biotech (EPA:DIM) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 12%

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 7.3% to €336

New minor risk - Share price stability

Consensus EPS estimates fall by 18%

Sartorius Stedim Biotech (EPA:DIM) Seems To Use Debt Quite Sensibly

Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Is Well Worth Watching

Consensus EPS estimates fall by 17%

Are Sartorius Stedim Biotech S.A. (EPA:DIM) Investors Paying Above The Intrinsic Value?

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of €1.44 per share at 0.5% yield

Full year 2022 earnings released: EPS: €9.51 (vs €4.50 in FY 2021)

Here's Why Sartorius Stedim Biotech (EPA:DIM) Can Manage Its Debt Responsibly

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2023

Does Sartorius Stedim Biotech (EPA:DIM) Deserve A Spot On Your Watchlist?

Sartorius Stedim Biotech S.A. to Report Fiscal Year 2022 Results on Jan 26, 2023

Sartorius Stedim Biotech S.A., Annual General Meeting, Mar 27, 2023

Less than half of directors are independent

Investor sentiment improved over the past week

Sartorius Stedim Biotech (EPA:DIM) Has A Pretty Healthy Balance Sheet

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Here's Why We Think Sartorius Stedim Biotech (EPA:DIM) Might Deserve Your Attention Today

Sartorius Stedim Biotech S.A. Provides Earnings Guidance for the Fiscal Year 2022

Estimating The Fair Value Of Sartorius Stedim Biotech S.A. (EPA:DIM)

Investor sentiment deteriorated over the past week

Sartorius Stedim Biotech S.A. (ENXTPA:DIM) entered into a definitive agreement to acquire Albumedix Ltd. from private investors for approximately £420 million.

We Think Sartorius Stedim Biotech (EPA:DIM) Can Stay On Top Of Its Debt

Second quarter 2022 earnings: EPS exceeds analyst expectations

Do Sartorius Stedim Biotech's (EPA:DIM) Earnings Warrant Your Attention?

Is Sartorius Stedim Biotech S.A. (EPA:DIM) Expensive For A Reason? A Look At Its Intrinsic Value

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent